GLP-1 agonists in HFpEF, DOACs for subclinical AF, renal denervation, and the matter of remaining in the profession are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
[ Ссылка ]
I. Obesity and HFpEF
GLP-1 Agonists in HFpEF With Obesity: Are We There Yet? [ Ссылка ]
Wegovy Scores HFpEF Benefits in People With Obesity [ Ссылка ]
- Semaglutide in Obese Patients With HFpEF [ Ссылка ]
- Rationale/Protocol Paper [ Ссылка ]
II. DOAC for Subclinical AF
- NOAH-AFNET 6 Rationale/Protocol [ Ссылка ]
- NOAH-AFNET 6 Trial Results [ Ссылка ]
III. Renal Denervation
ReCor Renal Denervation System Safe, Effective: FDA Panel [ Ссылка ]
FDA Panel Split on Efficacy of Spyral Renal Denervation [ Ссылка ]
SPYRAL HTN-ON MED [ Ссылка ]00455-X/fulltext
IV. Maintenance of Certification
As MOC Debate Heats Up, Cardiology Societies Weigh In [ Ссылка ]
Features
Mandrola's 5 Things to Look for at the Upcoming ESC 2023
[ Ссылка ]
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
[ Ссылка ]
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
[ Ссылка ]
Questions or feedback, please contact: news@medscape.net
